ADC Therapeutics SA (ADCT) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call shows mixed signals: moderate revenue growth and reduced losses are positive, but increased COGS and lack of clarity in trial timelines are concerning. The Q&A session reveals management's vagueness on crucial data points, which may dampen investor confidence. Although strategic plans are promising, short-term financial health is uncertain. With no significant catalysts or partnerships announced, the stock is likely to remain stable in the short term.
Key Financial Performance
Net Product Revenues $20.0 million in Q1 2026 compared to $17.4 million in Q1 2025, representing an increase driven primarily by normal quarter-to-quarter variability in customer ordering with underlying demand broadly stable.
Licensing Revenues and Royalties Lower in Q1 2026 compared to Q1 2025 due to a $5 million milestone received from a partner in the prior year period.
Cost of Product Sales Increased by $1.6 million to $3.6 million in Q1 2026, reflecting a shift in the allocation of certain personnel costs due to a change in focus from research and development activities to commercial manufacturing activities.
Total Operating Expenses (Non-GAAP) $42.9 million in Q1 2026, down by 13% compared to Q1 2025, primarily driven by lower R&D expenses.
Net Loss (GAAP) $33 million in Q1 2026 or $0.21 per share, compared to $38.6 million or $0.36 per share in Q1 2025, primarily due to reduced R&D expenses.
Net Loss (Non-GAAP) $19.7 million in Q1 2026 compared to $24 million in Q1 2025, primarily due to reduced R&D expenses.
Cash and Cash Equivalents $231 million at the end of Q1 2026 compared to $261.3 million as of December 31, 2025, maintaining an expected cash runway at least into 2028.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ZYNLONTA net product revenues: First quarter net product revenues were $20.0 million, up from $17.4 million in the prior year's first quarter. The increase was driven by normal quarter-to-quarter variability in customer ordering with underlying demand broadly stable.
LOTIS-5 trial: Phase III confirmatory trial of ZYNLONTA plus rituximab. Top line data expected before the end of June 2026, potentially expanding use into earlier lines of therapy in DLBCL.
LOTIS-7 trial: Enrollment of approximately 100 patients at the selected dose level of ZYNLONTA plus glofitamab expected to complete in Q2 2026, with full data anticipated by year-end.
Indolent lymphomas trials: Data publication expected between the end of 2026 and mid-2027 for ZYNLONTA in combination with rituximab and as a monotherapy for relapsed or refractory follicular and marginal zone lymphomas.
Market expansion for ZYNLONTA: Focus on expanding ZYNLONTA use into earlier lines of therapy in DLBCL and into indolent lymphomas. Potential peak annual revenues of $600 million to $1 billion in the U.S. with regulatory approval and compendia listing.
Cost management: Reduced total operating expenses by 13% versus Q1 2025 on a non-GAAP basis. Ended Q1 2026 with a cash balance of $231 million, maintaining expected cash runway into 2028.
Regulatory and strategic milestones: Plans to submit a supplemental biologics license application to the FDA by year-end 2026 for LOTIS-5, with potential publication and compendia inclusion in the first half of 2027.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approval Risks: The company is awaiting the LOTIS-5 trial readout and subsequent regulatory approval for ZYNLONTA in combination with rituximab. Any unfavorable results or delays in regulatory approval could impact the company's ability to expand its market and revenue potential.
Revenue Dependency on ZYNLONTA: The company's financial performance heavily relies on ZYNLONTA's success. Any challenges in expanding its use into earlier lines of therapy or indolent lymphomas could limit revenue growth.
Cost Management Challenges: While the company has reduced operating expenses, maintaining cost discipline while pursuing multiple clinical trials and regulatory approvals could strain financial resources.
Market Competition: ZYNLONTA operates in a competitive market for DLBCL treatments. The presence of alternative therapies could impact its market share and revenue growth.
Supply Chain and Manufacturing Costs: The increase in cost of product sales due to a shift in personnel costs from R&D to commercial manufacturing highlights potential challenges in managing manufacturing expenses efficiently.
Economic and Financial Risks: The company reported a net loss for the quarter, and its financial health depends on achieving milestones and revenue growth. Any delays or failures in clinical trials or regulatory approvals could exacerbate financial losses.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
LOTIS-5 Trial: Top line data for the Phase III confirmatory trial of ZYNLONTA plus rituximab is expected before the end of June 2026. Assuming positive results, a supplemental biologics license application will be submitted to the FDA by year-end, with potential publication and compendia inclusion in the first half of 2027 and confirmatory approval to follow thereafter.
LOTIS-7 Trial: Enrollment of approximately 100 patients at the selected dose level of ZYNLONTA plus glofitamab is expected to be completed in the second quarter of 2026, with full data anticipated by year-end. Assuming positive results, compendia inclusion and regulatory strategies will be pursued.
Indolent Lymphomas Studies: Data publication is anticipated between the end of 2026 and mid-2027 for ZYNLONTA in combination with rituximab for relapsed or refractory follicular lymphoma and as a monotherapy for relapsed or refractory marginal zone lymphoma. Regulatory and competitive strategies will be assessed once sufficient data are available.
Revenue Growth Projections: ZYNLONTA is projected to achieve peak annual revenues of $600 million to $1 billion in the U.S., driven by expansion into earlier lines of therapy in DLBCL and indolent lymphomas, assuming compendia listing and regulatory approval. Revenue growth acceleration is expected starting in 2027.
Cash Runway: The company expects its cash runway to last at least into 2028, supported by a cash balance of $231 million as of Q1 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you clarify if the database is locked at this point and when you reach the 262 events? What are the drivers that will allow you to unblind the data?
A:The database is not locked yet, and the company remains blinded to the data. Once the database is locked and statistical analysis is completed, top-line data will be disclosed. The company is on track to share the data this quarter.
Q:From a timing perspective, is there anything more on reaching the 262 events?
A:The company is not commenting on the exact timing of reaching the 262 events but reiterated that they are on track to disclose top-line results this quarter.
Q:Have the site-level interventions to address early dropout and censoring improved censoring rates?
A:The CEO could not comment further but mentioned that the last IDMC safety review occurred last fall, and the recommendation was to proceed as is.
Q:What is driving the $20 million in Q1 sales growth, and is there a trend?
A:The $20 million in Q1 sales represents 15% annual growth. The CEO noted variability in quarterly sales and stated it is too soon to call it a trend. The company is encouraged by maintaining market share in a competitive environment.
Q:What details will be disclosed in the LOTIS-5 top-line announcement?
A:The company plans to share information on primary endpoints, including median PFS, hazard ratios, key secondary endpoints, and top-line safety data. Sub-analyses and additional details will be shared later in the year at medical conferences or publications.
Q:Has the company entered a quiet period for LOTIS-5?
A:Yes, the company has been in a quiet period since April 1, except for the earnings call.
Q:Will the LOTIS-5 top-line data include information on overall survival (OS)?
A:Yes, the company will provide information on overall survival trends and other key secondary endpoints, but the maturity of OS data at the time of disclosure is unclear.
Q:Will the reallocation of R&D personnel costs to cost of goods (COGS) continue?
A:Yes, this reallocation will continue in all subsequent quarters, leading to an increase in COGS.
Q:What are the expected impacts of positive LOTIS-5 top-line results on ZYNLONTA's prescription and review?
A:If positive, the company plans to prepare an sBLA submission by the end of this year, with potential approval next year. Revenue impact is expected to begin next year, with promotion starting after formal approval.
Q:What is the timeline and value of IITs in marginal zone and follicular lymphoma?
A:Data from IITs will be disclosed between the end of this year and mid-next year, with publications and compendia submissions following. Regulatory approaches for lymphomas are being evaluated.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the timing of reaching 262 events, censoring rate improvements, and the maturity of overall survival data for LOTIS-5. Additionally, they used vague language regarding sales trends and did not provide concrete evidence to support their statements.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Ameet capital
Ameet line
Carmona CFO
Carmona result
Communications Head
Corporate Communications
Cost product
DLBCL ZYNLONTA
DLBCL lymphoma
FDA end
Head Investor
Licensing revenue
Monday conference
Officer Carmona
RD Ameet
RD reduction
ZYNLONTA LOTIS
ZYNLONTA agent
ZYNLONTA combination
ZYNLONTA glofitamab
ZYNLONTA monotherapy
ZYNLONTA patient
ZYNLONTA place
ZYNLONTA potential
ZYNLONTA product
ZYNLONTA profile
ZYNLONTA program
ZYNLONTA remainder
allocation
approval LOTIS
balance
compendia inclusion
end mid
end publication
increase
line LOTIS
lymphoma ZYNLONTA
meeting
milestone
readout
trial ZYNLONTA
ADCT Transcript
ADC Therapeutics SA (ADCT) Q1 2026 Earnings Call Transcript
Unknown5-4
The earnings call shows mixed signals: moderate revenue growth and reduced losses are positive, but increased COGS and lack of clarity in trial timelines are concerning. The Q&A session reveals management's vagueness on crucial data points, which may dampen investor confidence. Although strategic plans are promising, short-term financial health is uncertain. With no significant catalysts or partnerships announced, the stock is likely to remain stable in the short term.
ADC Therapeutics SA (ADCT) Q4 2025 Earnings Call Transcript
Positive3-10
The earnings call summary shows strong financial performance with increased revenues and reduced losses. The company's market expansion strategy for ZYNLONTA and a strengthened cash position are promising. The Q&A section highlights confidence in LOTIS-5 timelines and market projections, with potential upside. Despite some strategic execution risks and management's vague responses on certain aspects, the overall sentiment is positive, especially with the anticipated LOTIS-5 readout. The absence of negative guidance and steady financial health supports a positive outlook for the stock price over the next two weeks.
ADC Therapeutics SA (ADCT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-15
ADC Therapeutics SA (ADCT) Q3 2025 Earnings Call Transcript
Unknown11-10
The earnings call presents mixed signals: promising trial updates and potential revenue growth from ZYNLONTA are offset by declining revenues and net losses. The Q&A reveals uncertainties in timelines and market adoption challenges. The cost-cutting measures and extended cash runway provide some financial stability, but the lack of specific guidance and potential regulatory hurdles temper optimism. Overall, the sentiment is neutral, as positive developments are balanced by financial and operational concerns.
ADCT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
